CMPI
Income statement / Annual
Last year (2021), Checkmate Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Checkmate Pharmaceuticals, Inc.'s net income was -$61.41 M.
See Checkmate Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
Research and Development Expenses |
$45.82 M
|
$26.72 M
|
$24.25 M
|
$18.17 M
|
General & Administrative Expenses |
$15.65 M
|
$10.19 M
|
$4.64 M
|
$2.82 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$15.65 M
|
$10.19 M
|
$4.64 M
|
$2.82 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$61.47 M
|
$36.90 M
|
$28.89 M
|
$20.99 M
|
Cost And Expenses |
$61.47 M
|
$36.90 M
|
$28.89 M
|
$20.99 M
|
Interest Income |
$100,000.00
|
$79,000.00
|
$197,000.00
|
$180,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$66,000.00
|
$188,000.00
|
$597,000.00
|
$180,000.00
|
EBITDA |
-$61.34 M |
-$36.72 M |
-$28.29 M |
-$20.81 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$0.00
|
-$4,000.00
|
$597,000.00
|
$180,000.00
|
Income Before Tax |
-$61.41 M
|
-$36.91 M
|
-$28.29 M
|
-$20.81 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
-$4,000.00
|
$0.00
|
$0.00
|
Net Income |
-$61.41 M
|
-$36.91 M
|
-$28.29 M
|
-$20.81 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
EPS |
-6.42 |
-3.86 |
-3.44 |
-2.53 |
EPS Diluted |
-6.42 |
-3.86 |
-3.44 |
-2.53 |
Weighted Average Shares Out |
$9.56 M
|
$9.56 M
|
$8.22 M
|
$8.22 M
|
Weighted Average Shares Out Diluted |
$9.56 M
|
$9.56 M
|
$8.22 M
|
$8.22 M
|
Link |
|
|
|
|